Medpace
MEDP
$620.48
+4.21%
Medpace Holdings is a late-stage contract research organization (CRO) that provides full-service drug development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device companies, supplemented by bioanalytical laboratory and imaging capabilities. The company occupies a differentiated niche in the healthcare services landscape, positioning itself as a specialized, high-touch partner for emerging biopharma sponsors rather than competing head-on with the mega-CROs for large-cap pharma contracts. The current investor narrative centers on a powerful post-earnings re-rating: after a sharp April 2026 selloff tied to cautious guidance and a broader large-cap loser list appearance, the stock staged a dramatic recovery, with a 55% single-day jump in February 2026 highlighting how liquidity and market structure can amplify moves in this mid-cap name. Attention now focuses on whether Medpace's 26.5% year-over-year revenue growth and expanding backlog can be sustained amid a mixed biotech funding environment, with analysts split between those seeing durable share gains and those flagging valuation and margin normalization risks.…
MEDP
Medpace
$620.48
Related headlines
Investment Opinion: Should I buy MEDP Today?
The synthesized recommendation is Hold, with a neutral bias. The core thesis is that Medpace's strong revenue growth and cash flow are offset by margin compression and a valuation that leaves little room for error, as evidenced by the analyst consensus target of $581.83, which is essentially at the current price of $587.52. While the company's niche focus and 26.5% revenue growth are attractive, the risk/reward is balanced at current levels.
Supporting evidence includes: 1) Revenue growth of 26.5% YoY in Q1 2026, significantly above the healthcare sector average; 2) TTM free cash flow of $737.82 million, providing a 4.6% FCF yield; 3) A conservative debt-to-equity ratio of 0.55 and $652.68 million in cash; and 4) The stock trades at a trailing PE of 35.91x, which is at the top of its historical range and above the typical 15-25x for premium CRO peers. The forward PE of 30.43x implies an 18% earnings growth expectation, which is reasonable but not conservative. The PEG ratio of 1.82 suggests the stock is fully valued relative to its growth.
The biggest risks that could invalidate the thesis are: 1) Further gross margin erosion below 27%, which would pressure earnings and the multiple; 2) A slowdown in biotech funding that reduces demand for CRO services; and 3) Analyst downgrades and estimate cuts that could trigger a de-rating. The rating would upgrade to Buy if gross margins stabilize above 30% and revenue growth accelerates above 30%, or if the PE compresses below 25x. It would downgrade to Sell if revenue growth decelerates below 15% or if gross margins fall below 25%. Relative to its history and peers, the stock appears fairly valued to slightly overvalued, with the market pricing in continued execution.
Sign up to view all
MEDP 12-Month Price Forecast
Medpace presents a balanced risk/reward profile at current levels. The company's strong revenue growth and cash flow generation are offset by significant gross margin erosion and a valuation that leaves little room for error. The analyst consensus is neutral, with the average target essentially at the current price, and recent downgrades suggest fading conviction. The key tension is whether Medpace can stabilize gross margins while sustaining its growth trajectory; if margins recover, the stock could re-rate higher, but continued erosion would likely trigger multiple compression. I would upgrade to bullish if gross margins stabilize above 30% and revenue growth accelerates, and downgrade to bearish if gross margins fall below 27% or revenue growth decelerates below 15%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Medpace's 12-month outlook, with a consensus price target around $581.83 and implied upside of -6.2% versus the current price.
Average Target
$581.83
0 analysts
Implied Upside
-6.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$370 - $692
Analyst target range
Medpace is covered by 12 analysts, with the consensus average target price of $581.83 sitting essentially at the current price of $587.52 — implying a marginal -1.0% downside to consensus. The recommendation field is listed as "none," but the institutional ratings history reveals a decidedly mixed picture: recent actions include Mizuho maintaining Outperform (July 2026), Baird downgrading to Neutral from Outperform (July 2026), Jefferies cutting to Hold from Buy (July 2026), and TD Cowen upgrading to Hold from Sell (February 2026). The distribution of recent ratings leans neutral-to-cautious, with several firms trimming their bullishness after the April 2026 volatility, suggesting the consensus is best characterized as neutral with a slight bullish tilt from the Outperform-rated holdouts. The fact that the average target is essentially at the current price indicates analysts collectively see the stock as fairly valued after its sharp recovery from the April lows. The target range is wide, spanning from a low of $370.00 to a high of $692.00 — a spread of $322, or roughly 55% of the current price — which signals significant disagreement about Medpace's trajectory. The high target of $692.00 implies roughly 17.8% upside and likely assumes multiple expansion back toward the upper end of the historical PE band, sustained 20%+ revenue growth, and stabilization of gross margins near 30%. The low target of $370.00 implies approximately 37% downside and prices in a scenario of margin compression, biotech funding deterioration, and competitive share loss to larger CROs. The wide spread, combined with the recent downgrades from Baird and Jefferies, suggests conviction is weakening and the stock is vulnerable to estimate revisions; the elevated short ratio of 7.98 further indicates that a meaningful cohort of investors is positioned for downside, setting up potential volatility around upcoming earnings or guidance updates.
Bulls vs Bears: MEDP Investment Factors
The bull case rests on Medpace's 26.5% revenue growth, strong free cash flow, and conservative balance sheet, which support a premium valuation. However, the bear case is gaining traction due to a 415 basis point gross margin decline, a PE at the top of its historical range, and an analyst consensus target that implies no upside. The most critical tension is whether Medpace can stabilize gross margins while sustaining its growth trajectory; if margins continue to erode, the premium multiple is at risk. Currently, the bear evidence appears slightly stronger given the margin compression and neutral analyst stance, but the bull case remains viable if margin trends reverse.
Bullish
- Revenue growth remains robust at 26.5% YoY: Q1 2026 revenue reached $706.60 million, up 26.5% from $558.57 million in Q1 2025, continuing a multi-quarter expansion. This growth rate significantly exceeds the broader healthcare sector and demonstrates Medpace's ability to capture share in the small and midsize biotech CRO niche.
- Strong free cash flow generation and cash build: TTM free cash flow stands at $737.82 million, yielding a healthy 4.6% FCF yield on the $16.20 billion market cap. Cash increased to $652.68 million in Q1 2026 from $497.05 million at year-end 2025, providing ample liquidity for buybacks and organic investments.
- Conservative balance sheet with low leverage: Debt-to-equity is only 0.55, and the company has no interest expense, indicating minimal financial risk. This strong balance sheet allows Medpace to weather biotech funding cycles and continue its aggressive share repurchase program.
- Analyst high target implies 17.8% upside: The highest analyst target price is $692.00, representing 17.8% upside from the current $587.52. This target likely assumes sustained 20%+ revenue growth and gross margin stabilization, reflecting confidence in Medpace's differentiated model.
Bearish
- Gross margin compression of 415 basis points: Gross margin declined to 27.78% in Q1 2026 from 31.93% in Q1 2025, a significant erosion that suggests pricing pressure or unfavorable trial mix. If this trend continues, it could undermine profitability and valuation multiples.
- Valuation at historical peak with PEG above 1: The trailing PE of 35.91x sits at the very top of its historical range (20.0x-35.7x), and the PEG ratio of 1.82 indicates the stock is not cheap relative to its growth rate. Any deceleration could trigger multiple compression toward 25-30x PE, implying 15-25% downside.
- Analyst consensus target implies no upside: The average analyst target price of $581.83 is essentially at the current price of $587.52, implying -1.0% downside. Recent downgrades from Baird and Jefferies to Neutral/Hold suggest fading conviction and potential estimate revisions.
- Revenue concentration in metabolic and oncology: Metabolic ($237.56 million) and Oncology ($201.24 million) together account for the majority of revenue. Any slowdown in biotech R&D spending in these therapeutic areas would disproportionately impact Medpace's growth story.
MEDP Technical Analysis
Medpace is in a sustained recovery uptrend, with the current price of $587.52 sitting at approximately 70.4% of its 52-week range (low of $373.00, high of $677.90) and up 18.07% over the past year. The stock has clawed back most of the ground lost during a brutal April 2026 drawdown that saw it fall from a $528.44 close on April 20 to $393.42 by April 23, a single-session collapse of roughly 22.6%. Trading at 70% of range signals the stock has momentum but is not yet overextended, leaving room toward the upper boundary while the 52-week low remains a distant 36.6% below current levels, consistent with the reported max drawdown of -36.61%. Recent momentum is mixed: the 1-month change of -1.58% shows a modest pullback, while the 3-month change of +25.72% and 6-month change of +30.44% confirm powerful intermediate-term strength. This divergence — flat-to-negative short-term action against a strongly positive 3-month trend — suggests a healthy consolidation or digestion phase rather than a trend reversal, especially since the stock remains 22.68 percentage points ahead of SPY on a 3-month relative-strength basis. The 1-month relative strength of -0.52% versus SPY's -1.06% indicates Medpace is roughly in line with a soft market, not underperforming materially. Key resistance sits at the 52-week high of $677.90, roughly 15.4% above the current price; a breakout above that level would confirm a new leg higher and likely draw momentum buyers. Support is anchored at the 52-week low of $373.00, about 36.5% below current levels, with intermediate support around the $530-$540 zone where the stock consolidated in July 2026. With a beta of 1.149, Medpace is roughly 15% more volatile than the broader market, meaning position sizing should account for amplified drawdowns — the April 2026 episode proved the stock can lose over a fifth of its value in days, and the short ratio of 7.98 suggests elevated short interest that can fuel sharp squeezes in either direction.
Beta
1.15
1.15x market volatility
Max Drawdown
-36.6%
Largest decline past year
52-Week Range
$373-$678
Price range past year
Annual Return
+25.0%
Cumulative gain past year
| Period | MEDP Return | S&P 500 |
|---|---|---|
| 1m | +7.3% | -2.4% |
| 3m | +35.7% | +2.2% |
| 6m | +34.6% | +14.8% |
| 1y | +25.0% | +14.6% |
| ytd | +8.7% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MEDP Fundamental Analysis
Medpace's revenue trajectory remains robustly growth-oriented: Q1 2026 revenue reached $706.60 million, up 26.5% year over year from $558.57 million in Q1 2025, continuing a multi-quarter expansion that has seen quarterly revenue climb from $528.10 million in Q2 2024 to the current level. The sequential progression — $603.31 million in Q2 2025, $659.90 million in Q3 2025, $708.45 million in Q4 2025, and $706.60 million in Q1 2026 — shows growth has plateaued near the $700 million quarterly mark, suggesting the year-over-year comparisons are being driven by the depressed 2025 base rather than sequential acceleration. Segment data reveals concentration risk: Metabolic ($237.56 million) and Oncology ($201.24 million) together account for the majority of revenue, while Cardiology ($56.26 million), Antiviral/Anti-Infective ($38.02 million), and CNS ($80.21 million) are smaller contributors. The heavy weighting toward metabolic and oncology trials ties Medpace's fortunes to biotech R&D spending in those therapeutic areas, and any funding slowdown in those verticals would disproportionately impact the growth story. Profitability is solid but showing margin pressure: Q1 2026 net income was $123.87 million on a 17.53% net margin, down from 20.52% in Q1 2025, while gross margin compressed to 27.78% from 31.93% a year earlier. The gross margin decline of over 400 basis points year over year is a notable red flag — it suggests either pricing pressure, higher pass-through costs, or a less favorable mix of trial complexity. Operating margin held up better at 20.03% versus 20.32% in the prior-year quarter, indicating that SG&A leverage partially offset the gross margin erosion. The balance sheet is conservatively positioned with a debt-to-equity ratio of 0.55 and $652.68 million in cash at the end of Q1 2026, up from $497.05 million at year-end 2025. Free cash flow remains a standout: TTM FCF of $737.82 million against a market cap of $16.20 billion implies a healthy FCF yield of roughly 4.6%, and Q1 2026 operating cash flow of $151.79 million comfortably covered the $6.81 million in capital expenditures. However, the current ratio of 0.74 is below 1.0, reflecting the company's reliance on deferred revenue and customer prepayments rather than a liquidity concern, and ROE of 98.27% is inflated by a relatively thin equity base from aggressive share buybacks — the company repurchased $540.92 million of stock in Q2 2025 and $371.90 million in Q1 2025, which has shrunk the equity cushion and amplified return metrics.
Quarterly Revenue
$706604000.0B
2026-03
Revenue YoY Growth
+26.5%
YoY Comparison
Gross Margin
27.8%
Latest Quarter
Free Cash Flow
$737819000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MEDP Overvalued?
Because Medpace is solidly profitable — Q1 2026 net income of $123.87 million and trailing EPS of $4.35 — the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 35.91x and a forward PE of 30.43x, with the 15.3% gap between the two implying the market expects meaningful earnings growth over the next twelve months, consistent with the consensus EPS estimate of $26.36 (which appears to be on a different share-count basis than the reported quarterly EPS). The forward multiple compression from 35.9x to 30.4x suggests investors are pricing in roughly 18% earnings growth, a reasonable expectation given the 26.5% revenue growth but tempered by the gross margin compression. On a price-to-sales basis, MEDP trades at 6.40x, while EV/EBITDA stands at 27.97x and EV/Sales at 5.72x — all elevated multiples that reflect the market's premium for a high-growth, asset-light CRO with strong cash generation. Peer comparison within the Medical Diagnostics & Research industry is challenging given the absence of a direct industry-average benchmark in the provided data, but Medpace's 6.40x PS and 35.9x PE are broadly in line with premium CRO peers like IQVIA and Charles River, which typically trade in the 15-25x PE range, suggesting MEDP carries a growth premium. The PEG ratio of 1.82 is above 1.0, indicating the stock is not cheap relative to its growth rate, and the PB ratio of 35.29x is extraordinarily high, reflecting the buyback-depleted equity base rather than a fundamental overvaluation. Historically, Medpace's PE has ranged from a low of roughly 20.0x (Q1 2025) to a high of 35.7x (Q2 2024), with the current 35.9x trailing PE sitting at the very top of that band. The PS ratio tells a similar story: the current 6.40x is well below the 19-24x range seen in 2024-2025, but that historical PS data appears to be computed on a different share-count or revenue basis, making direct comparison unreliable. What is clear is that the stock is priced for continued execution — any deceleration in revenue growth or further gross margin erosion would likely trigger multiple compression toward the 25-30x PE range, implying 15-25% downside from current levels.
PE
35.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 18x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.0x
Enterprise Value Multiple
Investment Risk Disclosure
Medpace faces financial and operational risks primarily from margin pressure and revenue concentration. Gross margin fell to 27.78% in Q1 2026 from 31.93% a year earlier, a 415 basis point decline that signals pricing pressure or higher pass-through costs. Net margin also compressed to 17.53% from 20.52%, and while operating margin held at 20.03%, the erosion in gross profitability could persist if trial complexity increases. Additionally, metabolic and oncology segments together represent over 60% of revenue, creating concentration risk if biotech funding in these areas slows. The current ratio of 0.74 is below 1.0, but this reflects deferred revenue rather than a liquidity crisis, as cash stands at $652.68 million.
Market and competitive risks include valuation compression and sector rotation. The trailing PE of 35.91x is at the high end of its historical range (20.0x-35.7x), and the PEG ratio of 1.82 suggests the stock is priced for perfection. With a beta of 1.149, Medpace is more volatile than the market, and any broad healthcare selloff could amplify losses. Recent analyst downgrades from Baird and Jefferies to Neutral/Hold indicate waning confidence, and the short ratio of 7.98 shows that a significant cohort is betting against the stock. Competitive pressures from larger CROs like IQVIA and Charles River could also limit Medpace's pricing power and market share gains.
The worst-case scenario involves a combination of margin compression, biotech funding deterioration, and multiple contraction. If gross margins continue to decline and revenue growth decelerates below 15%, the stock could retest its 52-week low of $373.00, representing a 36.5% downside from the current price of $587.52. The analyst low target of $370.00 aligns with this bearish scenario, implying a 37% loss. Given the stock's history of sharp drawdowns—including a 22.6% single-day drop in April 2026 and a max drawdown of -36.61%—investors could face significant capital erosion in an adverse scenario.
FAQ
The key risks include: 1) Financial risk: gross margin compression of 415 basis points YoY to 27.78% could continue, pressuring profitability; 2) Competitive risk: larger CROs like IQVIA and Charles River could take market share, especially if biotech funding tightens; 3) Macro risk: with a beta of 1.149, the stock is more volatile than the market, and a healthcare sector rotation could amplify losses; 4) Company-specific risk: revenue concentration in metabolic and oncology (over 60% of revenue) makes Medpace vulnerable to funding slowdowns in those therapeutic areas. The short ratio of 7.98 also indicates bearish sentiment that could exacerbate downside.
The 12-month forecast has three scenarios: bull case (25% probability) with a target range of $650-$692, assuming gross margin recovery and sustained 25%+ revenue growth; base case (50% probability) with a target range of $560-$600, assuming stable growth and margins; and bear case (25% probability) with a target range of $370-$450, assuming margin erosion and revenue deceleration. The base case is most likely, with the stock trading around the analyst average target of $581.83. The key assumption is that gross margins stabilize around 28% and revenue growth remains above 20%.
MEDP appears fairly valued to slightly overvalued. The trailing PE of 35.91x is at the top of its historical range (20.0x-35.7x), and the forward PE of 30.43x implies an 18% earnings growth expectation. The PEG ratio of 1.82 is above 1.0, indicating the stock is not cheap relative to its growth. Compared to premium CRO peers like IQVIA and Charles River, which trade in the 15-25x PE range, MEDP carries a growth premium. The PS ratio of 6.40x and EV/EBITDA of 27.97x are also elevated. The market is pricing in continued execution, and any disappointment could lead to multiple compression.
MEDP is a good buy only for investors with a high risk tolerance and a long-term horizon, as the current risk/reward is balanced. The stock trades at $587.52, with the analyst average target of $581.83 implying slight downside, and the high target of $692 offering 17.8% upside. The biggest downside risk is a retest of the 52-week low of $373, which would represent a 36.5% loss. However, the company's 26.5% revenue growth and strong free cash flow provide fundamental support. For those who believe in the long-term growth of the CRO industry and Medpace's niche, it could be a good buy on dips, but at current levels, it is fairly valued.
MEDP is more suitable for long-term investment (minimum 2-3 years) given its growth stage, volatility, and lack of dividend. The company is in a high-growth phase with 26.5% revenue growth, but the stock is volatile (beta 1.149) and has experienced a 36.61% max drawdown. Short-term trading is risky due to sharp swings like the 22.6% single-day drop in April 2026 and the 55% jump in February 2026. The absence of a dividend (payout ratio 0) means returns depend entirely on capital appreciation. Long-term investors can benefit from the secular growth in biotech R&D outsourcing, but should be prepared for interim volatility.